SCM
DNTH icon

Soleus Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Soleus Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$3M – 99
2024
Q1 		$3M Buy
+100,000
New +$2.17M 0.22% 72
2021
Q3 		– Sell
-5,625
Closed -$880K – 73
2021
Q2 		$880K Sell
5,625
-625
-10% -$115K 0.14% 60
2021
Q1 		$1.18M Buy
+6,250
New +$1.05M 0.21% 62

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Soleus Capital Management's DNTH Position: Q2 2024 in Review

Soleus Capital Management sold out of Dianthus Therapeutics (DNTH) in Q2 2024, closing a stake of 100,000 shares — an estimated $3M sold.

Soleus Capital Management first reported a position in DNTH in Q1 2021 and held it in 3 quarters. The position peaked at $3M in Q1 2024. 74 funds tracked by Wall St. Rank hold DNTH as of Q2 2024.

  • Soleus Capital Management reported no remaining Dianthus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Soleus Capital Management sold 100,000 Dianthus Therapeutics shares in Q2 2024, an estimated $3M.
  • Soleus Capital Management first reported a position in Dianthus Therapeutics in Q1 2021 and held it in 3 quarters.
  • Soleus Capital Management's Dianthus Therapeutics position peaked at $3M in Q1 2024.
  • 74 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2024.

Based on Soleus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.